RAPT — Rapt Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- $68.06m
- -$46.78m
- 11
- 43
- 13
- 11
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 5.04 | 3.81 | 1.53 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 43.6 | 58.3 | 73 | 87.3 | 127 |
Operating Profit | -43.6 | -53.2 | -69.2 | -85.8 | -127 |
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -42.3 | -51.9 | -69.2 | -83.8 | -117 |
Provision for Income Taxes | |||||
Net Income After Taxes | -43 | -52.9 | -69.2 | -83.8 | -117 |
Net Income Before Extraordinary Items | |||||
Net Income | -43 | -52.9 | -69.2 | -83.8 | -117 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -43 | -52.9 | -69.2 | -83.8 | -117 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.89 | -2.19 | -2.53 | -2.58 | -3.05 |